Evotec, Takeda collaborate on strategic RNA targeting drug discovery and development

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Evotec SE and Takeda Pharmaceutical Company Ltd. have entered into a multi-RNA target alliance to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login